Plain-English translation of NCT06397911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called that you inject under your skin to treat moderate-to-severe eczema in adults. The study will compare to a placebo (inactive injection) to see if the medication works better at reducing itching, redness, and other eczema symptoms. About 90 people will participate, and the entire study lasts up to 28 weeks.
Many people with severe eczema don't improve enough with the creams and ointments currently available. This medication is designed to work differently—by targeting specific immune system pathways—to help people whose eczema hasn't responded well to standard treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will come to the clinic for a 4-week screening period to confirm your eligibility. Then you will receive 5 injections under your skin over a 12-week treatment period, either of the new medication or a placebo—you won't know which one. After that, you'll be followed for another 12 weeks to see how you're doing. You'll track your eczema symptoms, itching, and any side effects throughout the study.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States